← Back to Search

Other

Immunotherapy Combinations for Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Available tumor tissue for biomarker analysis
Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
Must not have
History of interstitial lung disease / pneumonitis
Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the safety and effectiveness of a new immunotherapy treatment for various types of cancer.

Who is the study for?
This trial is for adults with certain advanced solid cancers that have spread and can't be removed by surgery. Participants should be relatively healthy (ECOG status of 0 or 1) and have a tumor that can be measured. They must also provide tissue samples for research. People with brain metastases, lung inflammation history, active cancer in the last two years (except some skin cancers), or recent serious neurological issues cannot join.
What is being tested?
The study tests combinations of immunotherapy drugs: relatlimab with nivolumab and BMS-986205, or relatlimab with nivolumab and ipilimumab. It aims to find out how safe these combinations are and how well they work against different types of advanced tumors in patients who haven't had immunotherapy before as well as those who have.
What are the potential side effects?
Possible side effects include immune-related reactions such as inflammation in various organs like the intestines or liver, skin rash, hormone gland problems (like thyroid dysfunction), fatigue, flu-like symptoms, infusion reactions during drug administration, and potential worsening of underlying conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have tumor tissue available for testing.
Select...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and its size can be measured.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had lung inflammation or scarring before.
Select...
My cancer has spread to my brain or is only active there.
Select...
I haven't had encephalitis, meningitis, or uncontrolled seizures in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2023 Phase 1 & 2 trial • 62 Patients • NCT03310619
43%
Neutrophil count decreased
29%
Anaemia
29%
White blood cell count decreased
14%
Blood uric acid increased
14%
Back pain
14%
Erythema
14%
COVID-19
14%
Headache
14%
Neurotoxicity
14%
Neutropenia
14%
Palpitations
14%
Dry eye
14%
Diarrhoea
14%
Dyspepsia
14%
Chills
14%
Oedema peripheral
14%
Cytokine release syndrome
14%
Pneumonia
14%
Aspartate aminotransferase increased
14%
International normalised ratio increased
14%
Lymphocyte count decreased
14%
Platelet count decreased
14%
Dehydration
14%
Hypokalaemia
14%
Hypomagnesaemia
14%
Bone pain
14%
Myalgia
14%
Pain in jaw
14%
Dizziness
14%
Nystagmus
14%
Confusional state
14%
Cough
14%
Dyspnoea
14%
Tachypnoea
14%
Alopecia
14%
Rash maculo-papular
14%
Embolism
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment3 Interventions
Relatlimab + Nivolumab + Ipilimumab
Group II: Arm AExperimental Treatment3 Interventions
Relatlimab + Nivolumab + BMS-986205
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986205
2017
Completed Phase 3
~1200
Ipilimumab
2015
Completed Phase 3
~3420
Relatlimab
2019
Completed Phase 2
~1150
Nivolumab
2015
Completed Phase 3
~4010

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,098,816 Total Patients Enrolled

Media Library

BMS-986205 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03459222 — Phase 1 & 2
Cancer Research Study Groups: Arm A, Arm B
Cancer Clinical Trial 2023: BMS-986205 Highlights & Side Effects. Trial Name: NCT03459222 — Phase 1 & 2
BMS-986205 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03459222 — Phase 1 & 2
~56 spots leftby Nov 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top